Armando Poeppl
University Health Network
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Armando Poeppl.
Science | 2011
Faiyaz Notta; Sergei Doulatov; Elisa Laurenti; Armando Poeppl; Igor Jurisica; John E. Dick
Proteins are identified that underlie the early commitment steps of human hematopoietic stem cell differentiation. Lifelong blood cell production is dependent on rare hematopoietic stem cells (HSCs) to perpetually replenish mature cells via a series of lineage-restricted intermediates. Investigating the molecular state of HSCs is contingent on the ability to purify HSCs away from transiently engrafting cells. We demonstrated that human HSCs remain infrequent, using current purification strategies based on Thy1 (CD90) expression. By tracking the expression of several adhesion molecules in HSC-enriched subsets, we revealed CD49f as a specific HSC marker. Single CD49f+ cells were highly efficient in generating long-term multilineage grafts, and the loss of CD49f expression identified transiently engrafting multipotent progenitors (MPPs). The demarcation of human HSCs and MPPs will enable the investigation of the molecular determinants of HSCs, with a goal of developing stem cell–based therapeutics.
Nature | 2011
Faiyaz Notta; Charles G. Mullighan; Jean C.Y. Wang; Armando Poeppl; Sergei Doulatov; Letha A. Phillips; Jing Ma; Mark D. Minden; James R. Downing; John E. Dick
Many tumours are composed of genetically diverse cells; however, little is known about how diversity evolves or the impact that diversity has on functional properties. Here, using xenografting and DNA copy number alteration (CNA) profiling of human BCR–ABL1 lymphoblastic leukaemia, we demonstrate that genetic diversity occurs in functionally defined leukaemia-initiating cells and that many diagnostic patient samples contain multiple genetically distinct leukaemia-initiating cell subclones. Reconstructing the subclonal genetic ancestry of several samples by CNA profiling demonstrated a branching multi-clonal evolution model of leukaemogenesis, rather than linear succession. For some patient samples, the predominant diagnostic clone repopulated xenografts, whereas in others it was outcompeted by minor subclones. Reconstitution with the predominant diagnosis clone was associated with more aggressive growth properties in xenografts, deletion of CDKN2A and CDKN2B, and a trend towards poorer patient outcome. Our findings link clonal diversity with leukaemia-initiating-cell function and underscore the importance of developing therapies that eradicate all intratumoral subclones.
Science | 2007
James A. Kennedy; Frédéric Barabé; Armando Poeppl; Jean C.Y. Wang; John E. Dick
Kelly et al. (Brevia, 20 July 2007, p. 337) questioned xenotransplant experiments supporting the cancer stem cell (CSC) hypothesis because they found a high frequency of leukemia-initiating cells (L-IC) in some transgenic mouse models. However, the CSC hypothesis depends on prospective purification of cells with tumor-initiating capacity, irrespective of frequency. Moreover, we found similar L-IC frequencies in genetically comparable leukemias using syngeneic or xenogeneic models.
Journal of Experimental Medicine | 2012
Alexandre P.A. Theocharides; Liqing Jin; Po-Yan Cheng; Tatiana K. Prasolava; Andrei V. Malko; Jenny M.-Y. Ho; Armando Poeppl; Nico van Rooijen; Mark D. Minden; Jayne S. Danska; John E. Dick; Jean C.Y. Wang
Inhibition of macrophage SIRPα–CD47 interactions mediates phagocytosis and clearance of acute myeloid leukemia stem cells.
Nature | 2011
Faiyaz Notta; Charles G. Mullighan; Jean C.Y. Wang; Armando Poeppl; Sergei Doulatov; Letha A. Phillips; Jing Ma; Mark D. Minden; James R. Downing; John E. Dick
This corrects the article DOI: 10.1038/nature09733
Cancer Research | 2015
Eric D.J. Bouchard; Edgard M. Mejia; Iris Gehrke; Armando Poeppl; Donna Hewitt; James B. Johnston; Spencer B. Gibson; Grant M. Hatch; Versha Banerji
We have previously shown that the NAD depletion following inhibition of NAMPT by the NA-mimetic FK866 leads to loss of mitochondrial membrane potential, depletion of cellular ATP, cytochrome C release and caspase activation in primary Chronic Lymphocytic Leukemia (CLL) cells in vitro, and that these events are coupled with an increased production of reactive oxygen species uncharacteristic of metabolic inhibition. In the present study we characterize the effect of NAD depletion on CLL mitochondria and the downstream mechanism of cell death. We profiled the mitochondrial respiration of CLL cells and control B-lymphocytes, by extracellular flux analysis, over the 48 hours following FK866 treatment and found time-dependant inhibition of respiratory capacity consistent with disruption of the electron transport chain (ETC) in CLL cells. This led to suppression of basal respiration concomitant with the rise in ROS and approximately one day before loss of cellular viability. Interestingly, Zap70-positive CLL cells exhibited increased mitochondrial respiration and respiratory capacity over Zap70-negative CLL cells, but responded similarly to NAMPT inhibition. Additionally, mitochondrial respiration was not effected by NAMPT inhibition in control B-lymphocytes. Increase autophagic flux, caspase-dependant apoptosis and mitochondrio-nuclear translocation of Apoptosis Inducing Factor (AIF) were detected by western blot. However, neither pan-caspase inhibition with Z-VAD-fmk nor inhibition of autophagy with 3-methyladenine were sufficient to prevent FK866-induced CLL cell death. We conclude that NAD depletion following inhibition of NAMPT leads to disruption of the mitochondrial ETC in CLL cells, leading to mitochondrial initiation of the intrinsic apoptosis pathway. As healthy B-lymphocytes are resistant to this NAD depletion, these downstream effects are also selective for malignant cells. We are currently working to characterize the roles of NAD and Zap70 in the regulation and function of the CLL ETC. This will not only lead to an improved understanding of CLL metabolism, but will also inform new therapeutic strategies that will effectively employ NAMPT inhibition to treat this yet-incurable disease. Citation Format: Eric DJ Bouchard, Edgard M. Mejia, Iris Gehrke, Armando G. Poeppl, Donna Hewitt, James B. Johnston, Spencer B. Gibson, Grant M. Hatch, Versha Banerji. NAMPT inhibition induces mitochondrial dysfunction leading to apoptosis in chronic lymphocytic leukemia cells. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3052. doi:10.1158/1538-7445.AM2015-3052
Nature Medicine | 2011
Kolja Eppert; Katsuto Takenaka; Eric R. Lechman; Levi Waldron; Björn Nilsson; Klaus H. Metzeler; Armando Poeppl; Vicki Ling; Joseph Beyene; Angelo J. Canty; Jayne S. Danska; Stefan K. Bohlander; Christian Buske; Mark D. Minden; Todd R. Golub; Igor Jurisica; Benjamin L. Ebert; John E. Dick
Proceedings of the National Academy of Sciences of the United States of America | 2004
Makoto Yoshimitsu; Takeya Sato; K. Tao; Jagdeep S. Walia; Vanessa I. Rasaiah; Gillian T. Sleep; Gary J. Murray; Armando Poeppl; John Underwood; Lori J. West; Roscoe O. Brady; Jeffrey A. Medin
Molecular Therapy | 2007
Sheng-Ben Liang; Makoto Yoshimitsu; Armando Poeppl; Vanessa I. Rasaiah; Jianhui Cai; Daniel H. Fowler; Jeffrey A. Medin
Analytical Biochemistry | 2005
Armando Poeppl; Gary J. Murray; Jeffrey A. Medin